本刊特点:CSCD核心期刊(2023-2024),SCIE(2024版), 科技核心期刊(2024自然科学),目次收录(维普),目次收录(万方),目次收录(知网),外文期刊,第二批认定学术期刊,
期刊基本信息
出版周期:月刊 级别:核心期刊
主管部门:教育部
主办单位:四川大学
编辑部:《信号转导与靶向治疗(英文)编辑部
中国国内刊号:CN51-1758/R
国际标准刊号:ISSN 2095-9907;EISSN2059-3635
杂志社联系方式
地址:四川省成都市人民南路17号四川大学华西医院《信号转导与靶向治疗》编辑部
邮编:610041
电话:028-85421753
传真:028-85164060
微信公众号:Sigtrans
官网邮箱:sttt@scu.edu.cn
官方网站:http://www.nature.com/sigtrans/
杂志征稿投稿要求
Guide for Authors
Aims and Scope
Signal Transduction and Targeted Therapy is an international, peer-reviewed, open-access journal that publishes original research articles and review articles related to all aspects of signal transduction in physiological and pathological processes, as well as signal transduction-targeted therapeutics in the form of biological agents and small molecular drugs used to treat human diseases such as cancer, cardiovascular diseases, autoimmune diseases, nervous system diseases, and others. This journal focuses on cutting-edge advances both experimentally and clinically.
Journal Details
Editors-in-Chief:
Carlo M. Croce
Institute of Genetics, The Ohio State University, USA
Kang Zhang
Institute for Genomic Medicine, University of California San Diego, USA
Yu-Quan Wei
State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, China
Editorial office:
Address: No. 17, Section 3, Renmin South Road, Chengdu, Sichuan, 610041, China
Tel: 86-28-85421753 Fax: 86-28-85164060
E-mail: sttt@scu.edu.cn
ARTICLE TYPES
……
作者指南更多详情:
https://www.nature.com/documents/sigtrans-gta.pdf